Nov 13, 2019

UK launch of VivaGel® BV

UK launch of VivaGel® BV


  • VivaGel® BV has been launched in the UK by Mundipharma
  • VivaGel® BV is available in Europe (including the UK) Over-The-Counter
  • Mundipharma has launched VivaGel® BV in multiple countries in Europe, with additional European countries expected soon
  • Launches are also planned in other Mundipharma regions, including Asia, and regulatory activities continue in multiple regions

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been launched in the UK under the brand Betafem® BV Gel. This launch follows the first European launches in June 2019, including in Germany and other countries.

To be sold under the Betadine® umbrella brand, VivaGel® BV is available Over-The-Counter (OTC) in Europe, without the need to see a doctor or obtain a prescription. Europe represents a large commercial opportunity for VivaGel® BV with access to more than 260 million women and Mundipharma continues to roll-out the product in the region.

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to see VivaGel® BV launched in the UK. Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV. We look forward to working with Mundipharma on further registrations and launches across the globe”.

Raman Singh, Mundipharma CEO, commented: “VivaGel® BV is an important addition to the Betadine® product portfolio, which continues to evolve to support women’s everyday health and well-being around the world. Together with Starpharma we look forward to realising our joint ambition for Betafem® and women’s health.”

Starpharma’s and Mundipharma’s teams continue to work proactively together on regulatory and roll-out activities of VivaGel® BV across Mundipharma’s regions.

About VivaGel® BV

VivaGel® BV is a novel, non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV. BV is the most common vaginal condition worldwide and twice as common as thrush. One in three women will experience BV and half of these women will have recurrent BV. VivaGel® BV is an Australian innovation – invented, fully developed and taken through to commercialisation by Starpharma.

BV is a troublesome and often recurrent condition that causes unpleasant vaginal odour and discharge symptoms that have significant social impact for women. BV has also been associated with a range of other serious reproductive health-related medical problems.

Download ASX Announcement: UK launch of VivaGel® BV (PDF, 74kb)

 This contains certain forward-looking statements.